It was discovered that ceritinib, an IGFR inhibitor first used to treat NSCLC, could sensitise HCC cells to sorafenib both in vitro and in xenograft and HCC mice models by inhibiting the IGF-1R/Akt pathway [319]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.